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INTRODUCTION
Endoscopic submucosal dissection (ESD) is a normal 
therapeutic technology that allows en bloc excision 
and complete excision for early gastrointestinal cancers 
or dysplastic lesions (1-6). One of the complications of 
gastrointestinal ESD is postoperative hemorrhaging.
Some researchers have shown that the average 
rate of post-ESD bleeding of colorectal carcinoma 
is 1.8% (5). However, in gastric carcinoma, the rate of 
post-ESD bleeding ranged from 5.3% to 15.6% (7). 
The use of antiplatelet (APT) agents has a far-reaching 
impact on gastrointestinal post-ESD bleeding (7-9). Al-
though some researchers believe that patients on APT 
agents or anticoagulants may increase the chance of 
gastrointestinal post-ESD bleeding, others have shown 
the opposite result (8-11). Low-dose aspirin (LDA) is 
commonly used for cerebrovascular and cardiovascular 
diseases (12-14). At present, several international orga-
nizations in the USA and Europe have made an effort in 
drafting guidelines to manage the use of anticoagulant 
and APT agents for patients during and after ESD (15-
17). In Japan, the guidelines recommend perioperative 
continuation of LDA for patients undergoing ESD pro-
cedures that have high bleeding risks (18). However, the 
data and literature are limited. Whether the continuous 
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ABSTRACT
Background/Aims: Endoscopic submucosal dissection has been widely accepted. At present, the number of 
antiplatelet (APT) users has been growing. Moreover, because of high risks of thromboembolism, some patients 
need to continuously receive APT agents. The relationship between hemorrhage and continuous therapy with 
low-dose aspirin (LDA) remains controversial.
Materials and Methods: A systematic search was conducted; studies were screened out- if data of no-antico-
agulant/APT drugs use and interrupted and continued-LDA use were reported separately. The Newcastle-scale 
was chosen to assess the quality of the included studies. Review Manager 5.2 was used for quality assessment 
statistical analysis, and the odd ratio (OR) and 95% confidence interval (CI) were calculated.
Results: Pooled data suggested a significantly higher bleeding ratio in the LDA-continued group compared to 
both the LDA-interrupted group (OR=2.05, 95% CI=1.05-3.99) and no-anticoagulant/APT group (OR=2.89, 95% 
CI=1.86-4.47). However, the LDA-interrupted group did not differ significantly from the no-anticoagulant/APT 
group. The en bloc resection rates of the LDA-continued group versus the LDA-interrupted group, the LDA-
continued group versus no-anticoagulant/APT group, and the LDA-interrupted group versus the no-anticoag-
ulant/APT group were similar (OR=0.82, 95% CI=0.21-3.24, p=0.78; OR=0.80, 95% CI=0.24-2.65, p=0.71; OR=1.41, 
95% CI=0.38-5.24, p=0.60, respectively).
Conclusion: There is an extremely high ratio of bleeding in the LDA-continued group compared to both the 
LDA-interrupted group and no-anticoagulant/APT group. All groups had similar ratios of en bloc resection.
Keywords: Endoscopic submucosal dissection, gastrointestinal neoplasms, antiplatelet agents, gastroentero-
logical hemorrhage, meta-analysis
Cite this article as: Wu W, Chen J, Ding Q, Yang D, Yu H, Lin J. Continued use of low-dose aspirin may increase risk of bleeding after 
gastrointestinal endoscopic submucosal dissection: A meta-analysis. Turk J Gastroenterol 2017; 28: 329-36.
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use of LDA increases the bleeding risk after gastrointestinal 
ESD remains controversial; this issue needs to be resolved (19). 
Therefore, a systematic search on the databases and a meta-
analysis were conducted to determine whether patients un-
dergoing ESD for gastrointestinal tumors are at risk of bleeding 
after continued use of LDA.
MATERIALS AND METHODS
Search Method and Methodological Quality Assessment
Ethics committee approval was obtained and the study was 
in adherence with the Declaration of Helsinki. We do not have 
the informed consent. Because we do not use the original data 
from patients, we just summary the data from others published 
literatures. Our search analyzed data from PubMed and Co-
chrane library updated in October 2015 and included a match-
ing essay on the effect of aspirin after gastrointestinal ESD. The 
algorithms used in the search included “Aspirin” [Mesh] OR 
“Platelet Aggregation Inhibitors” [Mesh] OR “Dalteparin” [Mesh] 
AND “Stomach Neoplasms” [Mesh] OR “Colorectal Neoplasms” 
[Mesh] AND “ESD.” The references in the searchable results were 
selected manually. The data were obtained by two separated 
evaluators.
The collected literature compared the risk of bleeding from 
continued-LDA use or from interrupted-LDA use with the risk 
from no-LDA use. Patients diagnosed with cancer or precancer-
ous lesions were included, and reviews, case reports, abstracts, 
and letters were excluded. The Newcastle-Ottawa scale was 
used to assess the quality of the included studies and the fun-
nel plot scale to assess the publication bias (20,21).
Data Extraction
The patients’ basic information incorporated the main APT 
agents, size and location of the lesions, length of the proce-
dures, en bloc resection, bleeding, and perforation rate. The lo-
cation of lesions and bleeding after ESD were defined accord-
ing to the literature (22,23).
Statistical Analysis
For all data, we computed the odds ratio (OR) and 95% con-
fidence interval (CI). The Collaboration’s RevMan 5.3 software 
(The Nordic Cochrane Center, The Cochrane Collaboration, Co-
penhagen, Denmark) was used for statistical analysis. The forest 
plot was used to confirm the rates of en bloc resection and 
bleeding in each group. Chi square and I2 tests were used to 
examine the statistical heterogeneity. If I2>50% and p<0.1, the 
random effects model was chosen; if there was no heterogene-
ity, the fixed-effects model was applied.
RESULTS
Assessment of the Selected Studies
A total of 305 relevant papers were collected using the key 
search words. Five full-text studies were chosen for the final 
analysis (10,11,24-26) (Figure 1). The Newcastle-Ottawa scale 
was used to assess the quality of the included studies (Table 1).
Detailed Information of the Selected Studies
The five selected publications included four historical cohort 
studies and one case-control study (10,11,24-26). Four studies 
involved gastric cancer and one involved colorectal cancer; 
four studies described tumor location and tumor size and two 
mentioned operation time and rate of perforation; all the stud-
ies were published from 2012 to 2015 (10,11,24,26) (Table 2). 
The information on age was introduced in five publications. 
The median age of the patients in the no-anticoagulant/APT 
group, LDA-continued group, and LDA-interrupted group 
ranged from 61.6 to 67 years, 66.8 to 75.9 years and 64.5 to 72.7 
years, respectively. The ratios of males to females in the five pa-
pers were as follows: 1627 to 671 in the no-anticoagulant/APT 
330  
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Figure 1. The PRISMA flowchart of literature review
Potentially relevant literature
identified and screened for
retrieval (n= 305)
Abstracts excluded because of
not relevant, letter, review
(n= 283)
Articles retrieved for full-text
evaluation (n= 22)
Articles excluded because of
non-comparative study (n= 12)
or other than endoscopic
submucosal dissection (n= 5)
Articles suitable for meta-
analysis (n= 5)
  Outcome/ 
 Selection exposure
Author 1 2 3 4 Comparability 1 2 3
Sanomura et al. (24) ★	 ★	 	 ★	 ★★	 ★	 	
Ninomiya et al. (11) ★	 ★	 	 ★	 ★	 ★	 	
Lim et al. (10) ★	 ★	 	 ★	 ★	 ★	 ★	 ★
Matsumura et al. (25) ★	 ★	 	 	 ★★	 ★	 ★	
Cho et al. (26) ★	 ★  ★ ★ ★  
Quality assessment of bias in the included studies was evaluated based on the Newcas-
tle-Ottawa quality assessment scale
Table 1. Quality assessment of bias in the included studies
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group, 190 to 54 in the LDA-continued group, and 185 to 42 in 
the LDA-interrupted group.
Bleeding Complication
Five studies with data available on bleeding included 271 pa-
tients who received LDA-continued treatment for thrombo-
embolic events before and after ESD therapies; they also in-
cluded 278 controls who received LDA-interrupted treatment 
(10,11,24-26). The average incidence of bleeding in the LDA-
continued group was up to 11.8% but was 5.4% in the LDA-in-
terrupted group. One study introduced a higher rate of bleed-
ing in the LDA-continued group, whereas the remaining four 
studies indicated no significant difference in the proportion 
of bleeding. We chose the fixed-effects model for pool analy-
sis because of the low heterogeneity among the five studies 
(p=0.54; I2=0%) (19,11,24-26). The result illustrated that there 
331
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     Patient ages,  Tumor location Tumor 
     mean±SD  (U/M/L or size 
 Study  Study Main APT or median Male/ right/left/ (mm, Operation En bloc Perforation 
Author design Disease groups agents (range) Female rectum)  median) time (min) resection (n)  (n)
Sanomura Historical Early LDA- Aspirin,  75.9±8.2 20/5 8/4/16 18.3 49.6 28 0 
et al. (24) cohort gastric continued ticlopidine, 
 study cancer  group (n=28) clopidogre,  
    cilostazol
   LDA-  72.7±9.1 44/12 11/20/35 16.6 45.3 63 3 
   interrupted  
   group (n=66)
Ninomiya  Historical Colorectal LDA- Aspirin, 67.0±11.1 19/9 15/8/8 35.4±18.9 83.6±59.0 30 2 
et al. (11) cohort tumors continued clopidogre, 
 study  group (n=31) Ticlopidine
   LDA-  66.9±11.2 12/1 5/1/7 35.7±18.9 86.3±63.8 13 1 
   interrupted 
   group (n=13) 
   No-  67.0±11.1 379/163 236/120/209 35.5±18.8 85.2±63.5 538 28 
   anticoagulant/ 
   APT group (n=565)
Lim Historical Early LDA- Aspirin, 67.60±7.807 135/37 20/56/96 47.8±15.02 - - - 
et al. (10) cohort gastric continued clopidogre, 
 study cancer  group (n=172) cilostazol
   LDA-  66.45±7.341 85/17 15/21/66 45.9±11.25 - - - 
   interrupted 
   group (n=102)
   No- 
   anticoagulant/ 
   APT group (n=1317)  61.61±9.321 923/394 116/428/773 45.5±13.91 - - -
Matsumura Case- Gastric LDA- Aspirin - - - - - - - 
et al. (25) control cancer continued 
 study  group (n=21)
   LDA-  - - - - - - - 
   interrupted 
   group (n=41)
Cho  Historical Gastric LDA- Aspirin, 66.8±9.6 16/3 12/3/4 15 - 17 - 
et al. (26) cohort cancer continued clopidogre, 
 study  group (n=19) other APTs
   LDA-  64.5±8.8 44/12 43/11/2 15 - 54 - 
   interrupted 
   group (n=56)
   No-  61.7±9.3 325/114 330/73/36 15 - 417 - 
   anticoagulant/ 
   APT group (n=439)
SD: standard deviation; L: lower; M: middle; U: upper; LDA: low-dose aspirin; APT: antiplatelet
Table 2. Details of included studies
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Figure 2. a-f. Forest plots were used to verify the relative effects of en bloc resection and adverse events of bleeding in each group. Results regarding the 
rate of post-ESD bleeding (a-c) and rate of en bloc resection are shown (d-f )
ESD: endoscopic submucosal dissection; CI: confidence interval; W: weight; OR: odds ratio; LDA: low-dose aspirin; APT: antiplatelet
a
b
c
d
e
f
was a significantly higher bleeding ratio in the LDA-contin-
ued group than in the LDA-interrupted group (OR=2.05, 95% 
CI=1.05-3.99, p=0.04; Figure 2a). According to the results of the 
funnel plots, there was no publication bias (Figure 3a).
Three of the trials with data available on bleeding included 
171 patients who perioperatively received LDA-interrupted 
treatment and 2321 controls who did not use anticoagulant/
APT agents (10,11,26). In the no-anticoagulant/APT group, 
the incidence of bleeding was 4.8%, but was 5.8% in the LDA-
interrupted group. The fixed-effects model was used for pool 
analysis because of the low heterogeneity among the three 
studies (p=0.43; I2=0%). There was no significant difference be-
tween the bleeding ratio in the LDA-interrupted group and no-
anticoagulant/APT group (OR=1.31, 95% CI=0.67-2.56, p=0.43; 
Figure 2b). This result suggests that the incidence of bleeding 
in the LDA-interrupted group was similar to that in the no-an-
ticoagulant/APT group. According to the result of the funnel 
plots, there was no publication bias (Figure 3b).
Data on bleeding were available for three trials, and they in-
cluded 222 patients who received continued-LDA treatment 
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Figure 3. a-f. Funnel plots were used to obtain evidence of publication bias. The results regarding the rate of post-ESD bleeding (a-c) and the rate of en 
bloc resection (d-f ) are shown
a b
c d
e f
for thromboembolic events during the period of ESD therapies 
and 2321 controls who did not use anticoagulant/APT treat-
ment (10,11,26). The incidence of bleeding in the LDA-contin-
ued group was up to 13.1%, but was 4.8% in the no-anticoagu-
lant/APT group. Significant heterogeneity did not exist among 
those publications (p=0.22; I2=34%); hence, the fixed-effects 
model was chosen for pool analysis. The result illustrated that 
there was a significantly higher bleeding ratio in the LDA-con-
tinued group compared to the no-anticoagulant/APT group 
(OR=2.89, 95% CI=1.86-4.47, p<0.00001; Figure 2c). According 
to the result of the funnel plots, there was no publication bias 
(Figure 3c).
En Bloc Resection
The incidence of en bloc resection was reported in three stud-
ies (11,24,26). These reported 213 lesions (n=78 in the LDA-
continued group and n=135 in the LDA-interrupted group). 
Significant heterogeneity did not exist among studies (p=0.44; 
I2=0 %); therefore, the fixed-effects model was used for pool 
analysis. No significant difference was found in the en bloc re-
section rate between the continued-LDA group and the inter-
rupted-LDA group (OR=0.82, 95% CI=0.21-3.24, p=0.78; Figure 
2d). According to the result of the funnel plots, there was no 
publication bias (Figure 3d).
Two reports compared the incidence of en bloc resection be-
tween the continued-LDA group and the no-anticoagulant/
APT group (11,26). The fixed-effects model was used for pool 
analysis because of the low heterogeneity between the two 
studies (p 0.34; I2=0%). There was no significant difference in 
the en bloc resection ratio between LDA-continued group 
and no-anticoagulant/APT group (OR=0.80, 95% CI=0.24-
2.65, p=0.71; Figure 2e). This result suggests that the inci-
dence of en bloc resection of the LDA-continued group was 
similar to that of the no-anticoagulant/APT group. According 
to the result of the funnel plots, there was no publication bias 
(Figure 3e).
Two reports with data available on en bloc resection included 
patients who perioperatively received LDA-interrupted treat-
ment and who did not use anticoagulant/APT agents (11,26). 
The fixed-effects model was used for pool analysis because 
of the low heterogeneity between the two studies (p=0.98; 
I2=0%). There was no significant difference in the en bloc resec-
tion ratio between LDA-continued group and no-anticoagu-
lant/APT group (OR=1.41, 95% CI=0.38-5.24, p=0.60); Figure 2f ). 
This result indicates that the incidence of en bloc resection of 
the LDA-continued group was similar to that of the no-antico-
agulant/APT group. According to the result of the funnel plots, 
there was no publication bias (Figure 3f ).
DISCUSSION
Endoscopic submucosal dissection is an advanced, complex 
endoscopic technique that is currently used for early gastro-
intestinal cancers or dysplastic lesions. Bleeding is a major 
procedural complication during ESD. Although the chance 
of bleeding after ESD is low, particular caution is neces-
sary because some delayed bleeding could result in severe 
adverse events, such as cardiovascular events and hypovo-
lemic shock. At present, the users of APT drugs have been 
growing because of prevention of thrombotic complications. 
Moreover, some patients cannot interrupt anticoagulants 
because of the high risk of thromboembolism. Clinical trials 
have shown that long-term use of anticoagulants decreases 
the risk of cardiovascular events, but at the expense of an in-
creased risk of delayed bleeding. However, there are no pub-
lished multicenter studies showing the relation between APT 
agents (such as aspirin) and post-ESD bleeding; there are only 
a few expert opinions and one single-center retrospective 
study. Therefore, this meta-analysis was devised to investigate 
whether continuous LDA use could increase the risk of post-
ESD bleeding and to obtain evidence for APT users based on 
evidence-based medicine.
The meta-analysis conclusively shows that the incidence of 
post-ESD bleeding in gastrointestinal tract has no difference 
between patients with no-LDA use and those with interrupt-
ed-LDA use; however, the incidence is higher in continued-
LDA users. In contrast, continued-LDA use, interrupted-LDA 
use, and the absence of LDA use show equal rates of en bloc 
resection.
Regarding connection between the use of antithrombotic 
drugs and the hazard for post-ESD bleeding, the results are 
complicated. Some researchers have shown that patients are 
at higher risk of bleeding during or after ESD with continuous 
LDA use (9,26,27). Others have shown the opposite result, indi-
cating that using the LDA continuously does not increase the 
hazard of bleeding (10,24). We conducted a comprehensive 
and multicenter literature search and found that using LDA 
continuously may enhance the risk of bleeding, corresponding 
to the reported observations of Cho et al. (26).
At present, some studies indicate that using aspirin may lead to 
post-ESD bleeding, but it does not increase long-term morbid-
ity or mortality; patients at high risk of cardiovascular and cere-
brovascular complications need to take aspirin continuously 
(26). Among the five articles included in this meta-analysis, two 
reported complications of thromboembolism when patients 
stopped taking aspirin (10,24). One study reported that two 
patients experienced cerebrovascular infarction and two ex-
perienced acute myocardial infarction when LDA was stopped 
in patients before ESD (24). In the Lim JH study, after discon-
tinuing the use of aspirin for 5 days, a patient experienced seri-
ous cerebral infarction and atrial fibrillation (10). Moreover, a 
multicenter survey showed that among the Japanese patients, 
incidence of cerebral infarctions was higher than that of severe 
post-ESD bleeding upon discontinuation of aspirin (28). The 
aforementioned studies indicate that the discontinuation of 
aspirin intake may lead to some serious events compared to its 
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continuation. The main reason for this phenomenon is that a 
patient who experienced cardiovascular and atherothrombot-
ic diseases may be more likely at severe risk of acute ischemic 
events with the cessation of aspirin. Therefore, an individualized 
approach that fully considers patients’ risk and benefit should 
be applied (29). Aspirin use should be stopped when a person 
has a low risk for thromboembolic disease. However, when a 
person has a high risk for thromboembolism, continuous as-
pirin use should be advised, despite the high risk of post-ESD 
bleeding. This is because thromboembolic events are more se-
rious than post-ESD bleeding, which can decrease a patient’s 
quality of life (26). ESD has an advantage over endoscopic mu-
cosal resection for en bloc resection (30). With regard to the 
result of gastrointestinal ESD, the en bloc resection rates were 
quite high in all three groups included in this meta-analysis, 
suggesting no effect of aspirin on en bloc resection.
Some studies reported that bleeding was associated with le-
sion size and tumor location; for example, the hazard of post-
ESD bleeding was higher when the lesions were located in the 
cecum, but it was difficult to stratify patients by these factors 
in our meta-analysis (31,32). There were also some unanswered 
questions regarding the bleeding of post-ESD and aspirin use. 
A recent study showed that the ratio of bleeding after ESD was 
higher in the anticoagulant agents group than in the nonanti-
coagulants agent group, 23.3% and 2%, respectively; however, 
the study did not examine the methods of drug use or which 
antithrombotic drugs may increase the rate of bleeding (27). 
In another study, the use of heparin caused a higher risk of de-
layed bleeding after gastric ESD (33). Takeuchi found that com-
bining LDA with warfarin and longer ESD operations increased 
the rate of post-ESD bleeding (27). Moreover, Satoshi showed 
that taking thienopyridine derivatives with aspirin increased 
the hazard of bleeding after ESD, particularly in gastric ESD (34). 
These issues warrant further studies.
This meta-analysis has several drawbacks. First, this paper in-
cluded only five nonrandomized controlled studies. No ran-
domized controlled study comparing the hazard of bleeding 
after gastrointestinal ESD between interrupted aspirin use and 
continuous aspirin use has been published. Second, the results 
of any meta-analysis are influenced by the quality of the indi-
vidual studies. Based on a quality assessment of the trials in-
cluded in our meta-analysis, it has been determined that they 
were not free from systematic bias. Some trials drew a negative 
conclusion that was potentially due to small sample size. Third, 
some patients may have used more than one type of anti-
thrombotic drug; the combination of APT and anticoagulation 
drugs may produce a slight bias. Further controlled trials are 
needed using larger, high-quality randomized samples.
Through a multicenter study, this meta-analysis showed that 
continuous aspirin use may increase the risk of bleeding after 
gastrointestinal ESD. Thus, patients treated with APT should be 
carefully monitored for post-ESD bleeding.
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